<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00313625</url>
  </required_header>
  <id_info>
    <org_study_id>2018.00</org_study_id>
    <secondary_id>FHCRC-2018.00</secondary_id>
    <secondary_id>CDR0000467231</secondary_id>
    <nct_id>NCT00313625</nct_id>
  </id_info>
  <brief_title>Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma</brief_title>
  <official_title>A Phase II Study of Intravenous Melphalan and Busulfan Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy, such as melphalan and busulfan, before a donor peripheral&#xD;
      blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the&#xD;
      patient's immune system from rejecting the donor's stem cells. When the healthy stem cells&#xD;
      from a donor are infused into the patient they may help the patient's bone marrow make stem&#xD;
      cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells&#xD;
      from a donor can make an immune response against the body's normal cells. Giving tacrolimus&#xD;
      and methotrexate before or after transplant may stop this from happening.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving melphalan together with busulfan&#xD;
      followed by donor peripheral stem cell transplant, tacrolimus, and methotrexate works in&#xD;
      treating patients with multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate transplant-related mortality in patients with multiple myeloma treated with a&#xD;
           myeloablative conditioning regimen comprising melphalan and busulfan followed by&#xD;
           HLA-matched, allogeneic peripheral blood stem cell transplantation (PBSCT) and&#xD;
           graft-vs-host disease prophylaxis with tacrolimus and methotrexate.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the disease response in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the 1-year progression-free survival and overall survival in patients treated&#xD;
           with this regimen.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Conditioning regimen: Patients receive melphalan IV over 30 minutes on day -6 and&#xD;
           busulfan IV over 3 hours on days -5 to -3.&#xD;
&#xD;
        -  Peripheral blood stem cell transplantation (PBSCT): Patients undergo HLA-matched,&#xD;
           related donor, allogeneic PBSCT on day 0.&#xD;
&#xD;
        -  Graft-versus-host disease (GVHD) prophylaxis: Patients receive tacrolimus IV&#xD;
           continuously or orally twice daily beginning on day -2 and continuing until day 80&#xD;
           followed by a taper until day 180 in the absence of GVHD or disease progression.&#xD;
           Patients also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 6 months for 2 years and&#xD;
      then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transplant-related mortality at 180 days</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease response (complete response)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 1 year</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of multiple myeloma&#xD;
&#xD;
               -  Stage I disease with disease progression during the second of ≥ 2 lines of prior&#xD;
                  therapy&#xD;
&#xD;
               -  Stage II or III disease, meeting 1 of the following criteria:&#xD;
&#xD;
                    -  Failed to achieve at least a partial response after ≥ 2 courses of prior&#xD;
                       therapy&#xD;
&#xD;
                    -  Progressive disease after ≥ 2 courses of prior therapy&#xD;
&#xD;
                    -  Presented with high-risk features at diagnosis, including any of the&#xD;
                       following:&#xD;
&#xD;
                         -  Cytogenetic abnormality&#xD;
&#xD;
                         -  Del 13 or 4,14 by fluorescent in situ hybridization (FISH)&#xD;
&#xD;
                         -  Elevated lactic dehydrogenase&#xD;
&#xD;
                         -  Beta 2 microglobulin &gt; 5.5&#xD;
&#xD;
                         -  Circulating peripheral blood plasma cells&#xD;
&#xD;
               -  Any stage disease with disease progression &gt; 6 months after prior autologous stem&#xD;
                  cell transplantation&#xD;
&#xD;
          -  Availability of an HLA-matched, related donor between 12 and 75 years of age*&#xD;
&#xD;
               -  No bone marrow donors NOTE: *Donors &gt; 75 years of age are eligible at the&#xD;
                  discretion of the principal investigator&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 70-100%&#xD;
&#xD;
          -  Creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
          -  Bilirubin ≤ 2.5 mg/dL&#xD;
&#xD;
          -  ALT/AST &lt; 2 times upper limit of normal&#xD;
&#xD;
          -  Cardiac ejection fraction ≥ 49%&#xD;
&#xD;
          -  DLCO ≥ 50% corrected&#xD;
&#xD;
          -  FEV_1 ≥ 60%&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No cirrhosis&#xD;
&#xD;
          -  No chronic inflammatory or fibrotic liver disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 6 months since prior autologous transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William I. Bensinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>April 11, 2006</study_first_submitted>
  <study_first_submitted_qc>April 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2006</study_first_posted>
  <last_update_submitted>September 20, 2010</last_update_submitted>
  <last_update_submitted_qc>September 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>William I. Bensinger</name_title>
    <organization>Fred Hutchinson Cancer Research Center</organization>
  </responsible_party>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

